Impact of adding maraviroc to antiretroviral regimens in patients with full viral suppression but impaired CD4 recovery
We reviewed the effect of adding maraviroc on CD4 cell counts in nine patients on antiretroviral therapy with full viral suppression but impaired CD4 cell recovery. There were no significant differences in changes in CD4 cell count, percentage of CD4 cells, or in the ratio of CD4/CD8 cells at 30 day...
Gespeichert in:
| Veröffentlicht in: | AIDS (London) 2009-09, Vol.23 (14), p.1911-1913 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1913 |
|---|---|
| container_issue | 14 |
| container_start_page | 1911 |
| container_title | AIDS (London) |
| container_volume | 23 |
| creator | STEPANYUK, Olena CHIANG, Tom S DEVER, Lisa L PAEZ, Sandra L SMITH, Sharon M PEREZ, George ENG, Robert H. K |
| description | We reviewed the effect of adding maraviroc on CD4 cell counts in nine patients on antiretroviral therapy with full viral suppression but impaired CD4 cell recovery. There were no significant differences in changes in CD4 cell count, percentage of CD4 cells, or in the ratio of CD4/CD8 cells at 30 days and 25 weeks of maraviroc therapy. Plasma endotoxin levels measured in four patients before and during maraviroc treatment also showed no significant differences. |
| doi_str_mv | 10.1097/QAD.0b013e32832f3c65 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_734017675</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>734017675</sourcerecordid><originalsourceid>FETCH-LOGICAL-c367t-3294a2a8c041852f2cfa85a6cae84a33848d15965303d56900423e53db27829e3</originalsourceid><addsrcrecordid>eNp9kU2LFDEQhoMo7rj6D0RyUU-9Vr6T4zLrx8KCCHpuatLpNdLdaZP0Lvvvjcyg4MFTQfG8T0G9hLxkcMHAmXdfLq8u4ABMBMGt4KPwWj0iOyaN6JQy7DHZAdeuc8LAGXlWyg8AUGDtU3LGnLLSgNiR--t5RV9pGikOQ1xu6YwZ72JOntZEcakxh5pT2-BEc7iNc1gKjQtdscaw1ELvY_1Ox22a6BEq27rmUEpMCz1slcZ2oUkGur-SzeDTXcgPz8mTEacSXpzmOfn24f3X_afu5vPH6_3lTeeFNrUT3EnkaD1IZhUfuR_RKtQeg5UohJV2YMppJUAMSjsAyUVQYjhwY7kL4py8PXrXnH5uodR-jsWHacIlpK30RkhgRhvVyDf_JXl7urRWN1AeQZ9TKTmM_Zpj-9pDz6D_XU3fqun_rabFXp3822EOw9_QqYsGvD4BWDxOY8bFx_KH48xpMFKJXzwnmJA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>20974886</pqid></control><display><type>article</type><title>Impact of adding maraviroc to antiretroviral regimens in patients with full viral suppression but impaired CD4 recovery</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>STEPANYUK, Olena ; CHIANG, Tom S ; DEVER, Lisa L ; PAEZ, Sandra L ; SMITH, Sharon M ; PEREZ, George ; ENG, Robert H. K</creator><creatorcontrib>STEPANYUK, Olena ; CHIANG, Tom S ; DEVER, Lisa L ; PAEZ, Sandra L ; SMITH, Sharon M ; PEREZ, George ; ENG, Robert H. K</creatorcontrib><description>We reviewed the effect of adding maraviroc on CD4 cell counts in nine patients on antiretroviral therapy with full viral suppression but impaired CD4 cell recovery. There were no significant differences in changes in CD4 cell count, percentage of CD4 cells, or in the ratio of CD4/CD8 cells at 30 days and 25 weeks of maraviroc therapy. Plasma endotoxin levels measured in four patients before and during maraviroc treatment also showed no significant differences.</description><identifier>ISSN: 0269-9370</identifier><identifier>EISSN: 1473-5571</identifier><identifier>DOI: 10.1097/QAD.0b013e32832f3c65</identifier><identifier>PMID: 19584703</identifier><language>eng</language><publisher>Hagerstown, MD: Lippincott Williams & Wilkins</publisher><subject>Aged ; AIDS/HIV ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; antiretroviral therapy ; Antiretroviral Therapy, Highly Active - methods ; Antiviral agents ; Biological and medical sciences ; CD4 antigen ; CD4 Lymphocyte Count ; CD8 antigen ; Cyclohexanes - therapeutic use ; Drug Evaluation ; Endotoxins ; Endotoxins - blood ; HIV Fusion Inhibitors - therapeutic use ; HIV Infections - drug therapy ; HIV Infections - immunology ; HIV Infections - virology ; HIV-1 - isolation & purification ; Human viral diseases ; Humans ; Immunodeficiencies ; Immunodeficiencies. Immunoglobulinopathies ; Immunopathology ; Infectious diseases ; Male ; Medical sciences ; Middle Aged ; Pharmacology. Drug treatments ; Retrospective Studies ; RNA, Viral - blood ; Treatment Outcome ; Triazoles - therapeutic use ; Viral diseases ; Viral diseases of the lymphoid tissue and the blood. Aids</subject><ispartof>AIDS (London), 2009-09, Vol.23 (14), p.1911-1913</ispartof><rights>2009 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c367t-3294a2a8c041852f2cfa85a6cae84a33848d15965303d56900423e53db27829e3</citedby><cites>FETCH-LOGICAL-c367t-3294a2a8c041852f2cfa85a6cae84a33848d15965303d56900423e53db27829e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=21960745$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19584703$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>STEPANYUK, Olena</creatorcontrib><creatorcontrib>CHIANG, Tom S</creatorcontrib><creatorcontrib>DEVER, Lisa L</creatorcontrib><creatorcontrib>PAEZ, Sandra L</creatorcontrib><creatorcontrib>SMITH, Sharon M</creatorcontrib><creatorcontrib>PEREZ, George</creatorcontrib><creatorcontrib>ENG, Robert H. K</creatorcontrib><title>Impact of adding maraviroc to antiretroviral regimens in patients with full viral suppression but impaired CD4 recovery</title><title>AIDS (London)</title><addtitle>AIDS</addtitle><description>We reviewed the effect of adding maraviroc on CD4 cell counts in nine patients on antiretroviral therapy with full viral suppression but impaired CD4 cell recovery. There were no significant differences in changes in CD4 cell count, percentage of CD4 cells, or in the ratio of CD4/CD8 cells at 30 days and 25 weeks of maraviroc therapy. Plasma endotoxin levels measured in four patients before and during maraviroc treatment also showed no significant differences.</description><subject>Aged</subject><subject>AIDS/HIV</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>antiretroviral therapy</subject><subject>Antiretroviral Therapy, Highly Active - methods</subject><subject>Antiviral agents</subject><subject>Biological and medical sciences</subject><subject>CD4 antigen</subject><subject>CD4 Lymphocyte Count</subject><subject>CD8 antigen</subject><subject>Cyclohexanes - therapeutic use</subject><subject>Drug Evaluation</subject><subject>Endotoxins</subject><subject>Endotoxins - blood</subject><subject>HIV Fusion Inhibitors - therapeutic use</subject><subject>HIV Infections - drug therapy</subject><subject>HIV Infections - immunology</subject><subject>HIV Infections - virology</subject><subject>HIV-1 - isolation & purification</subject><subject>Human viral diseases</subject><subject>Humans</subject><subject>Immunodeficiencies</subject><subject>Immunodeficiencies. Immunoglobulinopathies</subject><subject>Immunopathology</subject><subject>Infectious diseases</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Pharmacology. Drug treatments</subject><subject>Retrospective Studies</subject><subject>RNA, Viral - blood</subject><subject>Treatment Outcome</subject><subject>Triazoles - therapeutic use</subject><subject>Viral diseases</subject><subject>Viral diseases of the lymphoid tissue and the blood. Aids</subject><issn>0269-9370</issn><issn>1473-5571</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kU2LFDEQhoMo7rj6D0RyUU-9Vr6T4zLrx8KCCHpuatLpNdLdaZP0Lvvvjcyg4MFTQfG8T0G9hLxkcMHAmXdfLq8u4ABMBMGt4KPwWj0iOyaN6JQy7DHZAdeuc8LAGXlWyg8AUGDtU3LGnLLSgNiR--t5RV9pGikOQ1xu6YwZ72JOntZEcakxh5pT2-BEc7iNc1gKjQtdscaw1ELvY_1Ox22a6BEq27rmUEpMCz1slcZ2oUkGur-SzeDTXcgPz8mTEacSXpzmOfn24f3X_afu5vPH6_3lTeeFNrUT3EnkaD1IZhUfuR_RKtQeg5UohJV2YMppJUAMSjsAyUVQYjhwY7kL4py8PXrXnH5uodR-jsWHacIlpK30RkhgRhvVyDf_JXl7urRWN1AeQZ9TKTmM_Zpj-9pDz6D_XU3fqun_rabFXp3822EOw9_QqYsGvD4BWDxOY8bFx_KH48xpMFKJXzwnmJA</recordid><startdate>20090910</startdate><enddate>20090910</enddate><creator>STEPANYUK, Olena</creator><creator>CHIANG, Tom S</creator><creator>DEVER, Lisa L</creator><creator>PAEZ, Sandra L</creator><creator>SMITH, Sharon M</creator><creator>PEREZ, George</creator><creator>ENG, Robert H. K</creator><general>Lippincott Williams & Wilkins</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7T7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>20090910</creationdate><title>Impact of adding maraviroc to antiretroviral regimens in patients with full viral suppression but impaired CD4 recovery</title><author>STEPANYUK, Olena ; CHIANG, Tom S ; DEVER, Lisa L ; PAEZ, Sandra L ; SMITH, Sharon M ; PEREZ, George ; ENG, Robert H. K</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c367t-3294a2a8c041852f2cfa85a6cae84a33848d15965303d56900423e53db27829e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Aged</topic><topic>AIDS/HIV</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>antiretroviral therapy</topic><topic>Antiretroviral Therapy, Highly Active - methods</topic><topic>Antiviral agents</topic><topic>Biological and medical sciences</topic><topic>CD4 antigen</topic><topic>CD4 Lymphocyte Count</topic><topic>CD8 antigen</topic><topic>Cyclohexanes - therapeutic use</topic><topic>Drug Evaluation</topic><topic>Endotoxins</topic><topic>Endotoxins - blood</topic><topic>HIV Fusion Inhibitors - therapeutic use</topic><topic>HIV Infections - drug therapy</topic><topic>HIV Infections - immunology</topic><topic>HIV Infections - virology</topic><topic>HIV-1 - isolation & purification</topic><topic>Human viral diseases</topic><topic>Humans</topic><topic>Immunodeficiencies</topic><topic>Immunodeficiencies. Immunoglobulinopathies</topic><topic>Immunopathology</topic><topic>Infectious diseases</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Pharmacology. Drug treatments</topic><topic>Retrospective Studies</topic><topic>RNA, Viral - blood</topic><topic>Treatment Outcome</topic><topic>Triazoles - therapeutic use</topic><topic>Viral diseases</topic><topic>Viral diseases of the lymphoid tissue and the blood. Aids</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>STEPANYUK, Olena</creatorcontrib><creatorcontrib>CHIANG, Tom S</creatorcontrib><creatorcontrib>DEVER, Lisa L</creatorcontrib><creatorcontrib>PAEZ, Sandra L</creatorcontrib><creatorcontrib>SMITH, Sharon M</creatorcontrib><creatorcontrib>PEREZ, George</creatorcontrib><creatorcontrib>ENG, Robert H. K</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>AIDS (London)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>STEPANYUK, Olena</au><au>CHIANG, Tom S</au><au>DEVER, Lisa L</au><au>PAEZ, Sandra L</au><au>SMITH, Sharon M</au><au>PEREZ, George</au><au>ENG, Robert H. K</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Impact of adding maraviroc to antiretroviral regimens in patients with full viral suppression but impaired CD4 recovery</atitle><jtitle>AIDS (London)</jtitle><addtitle>AIDS</addtitle><date>2009-09-10</date><risdate>2009</risdate><volume>23</volume><issue>14</issue><spage>1911</spage><epage>1913</epage><pages>1911-1913</pages><issn>0269-9370</issn><eissn>1473-5571</eissn><abstract>We reviewed the effect of adding maraviroc on CD4 cell counts in nine patients on antiretroviral therapy with full viral suppression but impaired CD4 cell recovery. There were no significant differences in changes in CD4 cell count, percentage of CD4 cells, or in the ratio of CD4/CD8 cells at 30 days and 25 weeks of maraviroc therapy. Plasma endotoxin levels measured in four patients before and during maraviroc treatment also showed no significant differences.</abstract><cop>Hagerstown, MD</cop><pub>Lippincott Williams & Wilkins</pub><pmid>19584703</pmid><doi>10.1097/QAD.0b013e32832f3c65</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0269-9370 |
| ispartof | AIDS (London), 2009-09, Vol.23 (14), p.1911-1913 |
| issn | 0269-9370 1473-5571 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_734017675 |
| source | MEDLINE; Journals@Ovid Complete; EZB-FREE-00999 freely available EZB journals |
| subjects | Aged AIDS/HIV Antibiotics. Antiinfectious agents. Antiparasitic agents antiretroviral therapy Antiretroviral Therapy, Highly Active - methods Antiviral agents Biological and medical sciences CD4 antigen CD4 Lymphocyte Count CD8 antigen Cyclohexanes - therapeutic use Drug Evaluation Endotoxins Endotoxins - blood HIV Fusion Inhibitors - therapeutic use HIV Infections - drug therapy HIV Infections - immunology HIV Infections - virology HIV-1 - isolation & purification Human viral diseases Humans Immunodeficiencies Immunodeficiencies. Immunoglobulinopathies Immunopathology Infectious diseases Male Medical sciences Middle Aged Pharmacology. Drug treatments Retrospective Studies RNA, Viral - blood Treatment Outcome Triazoles - therapeutic use Viral diseases Viral diseases of the lymphoid tissue and the blood. Aids |
| title | Impact of adding maraviroc to antiretroviral regimens in patients with full viral suppression but impaired CD4 recovery |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T15%3A24%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Impact%20of%20adding%20maraviroc%20to%20antiretroviral%20regimens%20in%20patients%20with%20full%20viral%20suppression%20but%20impaired%20CD4%20recovery&rft.jtitle=AIDS%20(London)&rft.au=STEPANYUK,%20Olena&rft.date=2009-09-10&rft.volume=23&rft.issue=14&rft.spage=1911&rft.epage=1913&rft.pages=1911-1913&rft.issn=0269-9370&rft.eissn=1473-5571&rft_id=info:doi/10.1097/QAD.0b013e32832f3c65&rft_dat=%3Cproquest_cross%3E734017675%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=20974886&rft_id=info:pmid/19584703&rfr_iscdi=true |